Use of granisetron in patients refractory to previous treatment with antiemetics

Carmichael, James; Keizer, H. J.; Cupissol, Didier; Milliez, J.; Scheidel, P.; Schindler, A. E.

doi:10.1097/00001813-199806000-00002

Cited by 90 publications

(124 citation statements)

References 0 publications

Supporting

Mentioning

123

Contrasting

Order By: Relevance

“…This was in contrast to the better efficacy of granisetron in the prevention of chemotherapy-induced nausea and vomiting, which was proven in a number of studies like those by Specter JI et al [14] Carmichael et al [15] and De Wit et al [16] So also in our study there was no significant advantage of one 5-HT3 receptor blocker over the other for the prevention of PONV over 24 hours.…”

Section: Discussioncontrasting

confidence: 65%

A Comparative Study of Ondansetron and Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day-Care Surgery

Kumar¹,

Remadevi²,

Pratheeba³

2016

jemds

View full text Add to dashboard Cite

CONTEXTA major factor behind this Day-Care surgery has been substantial savings in medical costs apart from increasing the convenience to the patient. From an anaesthetic viewpoint, one of the primary goals with respect to outpatient anaesthesia is prompt recovery with minimal side effects and quick discharge. AIMSTo compare the efficacy and side effects of ondansetron and granisetron in the prevention of Postoperative Nausea and Vomiting (PONV) in female patients of reproductive age group undergoing Day-Care surgery. SETTINGS AND DESIGNRandomised double blind. METHODS AND MATERIAL150 female patients, ASA I and II, between the age of 18-45 yrs. undergoing Day-Care surgery. The patients were randomly allocated to one of the three groups (50 in each group). Group C (n=50): Control group. Received normal saline 2 mL intravenously. Group G (n=50): Granisetron group received Inj. Granisetron 1 mg IV made to 2 mL with normal saline. Group O (n=50): Ondansetron group. Received Inj. Ondansetron 4 mg IV in 2 mL. Incidence of PONV was studied during two periods after surgery in the PACU (0-2 hrs.) and in the ward (2-6 hrs.). Patients were asked to rate nausea on a four-point scale as 0 -none, 1 -mild, 2 -moderate or 3 -severe. A telephonic interview was held with the patient 24 hours after surgery. This assessed the incidence of retching/vomiting, the incidence and severity of nausea and pain during the 24 hours after discharge. STATISTICAL ANALYSISANOVA, Chi-square, Fisher's Exact test was done. RESULTS9 patients (18%) in the placebo group suffered from vomiting, whereas only 6 (12%) in the ondansetron group and 3 (6%) in the granisetron group were affected. The incidence of PONV without prophylaxis was 20% with Group G (Inj. granisetron) was 10% and Group O (Inj. ondansetron) was 16%. This difference was not statistically significant in the 2-6 hours' period, Group G (Inj. granisetron) was found to be more effective than Group C (placebo) (p <0.05) in preventing vomiting. In the post discharge period (6-24 hrs.), Group G (Inj. granisetron) was more effective than Group C (placebo) (p <0.005) and Group O (Inj. ondansetron) (p <0.05) in the prevention of PONV. CONCLUSIONWe conclude either granisetron and ondansetron is equally effective for the control of PONV in the first 6 hours after Day-Care surgery, granisetron is more effective than ondansetron in the post-discharge period. KEYWORDS5-HT3 Antagonists, Granisetron, Ondansetron, Day-Care Surgery, Post-Operative Nausea and Vomiting. HOW TO CITE THIS ARTICLE:Kumar VS, Remadevi R, Pratheeba N. A comparative study of ondansetron and granisetron in the prevention of post-operative nausea and vomiting (PONV) in day-care surgery.

show abstract

Section: Discussioncontrasting

confidence: 65%

A Comparative Study of Ondansetron and Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day-Care Surgery

Kumar¹,

Remadevi²,

Pratheeba³

2016

jemds

View full text Add to dashboard Cite

show abstract

“…2) [17]. However, patients receiving doses of cisplatin in excess of 50 mg/m 2 had lower complete response rates (25.0%-57.1%) than those receiving other cytostatic agents (59.3%-67.9%).…”

Section: Breakthrough Emesis and Treatment Failurementioning

confidence: 97%

“…Cisplatin is one of the most highly emetogenic agents, with doses of 50 mg/m 2 or more inducing nausea and vomiting within 24 hours in more than 90% of patients not administered antiemetic prophylaxis. Even in those patients receiving appropriate prophylaxis during multiple-cycle chemotherapy, the risk of vomiting associated with cisplatin is 20% greater than with non-cisplatin-containing regimens [17]. Agents with moderately high emetogenic potentials include methotrexate, doxorubicin, cyclophosphamide, and carboplatin, while vinblastine and bleomycin are considered to have low emetogenicity as monotherapy products [7].…”

Section: Risk Factors For the Development Of Acute Nausea And Vomitingmentioning

confidence: 99%

“…This specificity obviates the severe and distressing extrapyramidal side effects sometimes associated with conventional antiemetics [17]. The introduction of the 5-HT 3 -receptor antagonists has represented a significant clinical advance in the prevention of CINV, particularly for patients receiving highly emetogenic cisplatin-containing chemotherapy, in whom the 5-HT 3 -receptor antagonists generally produce superior efficacy to high-dose metoclopramide [1].…”

Section: The Accepted Gold Standardmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Schnell¹

2003

The Oncologist

186

167

View full text Add to dashboard Cite

Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 6-7 days after therapy), or anticipatory (occurring prior to chemotherapy administration). Breakthrough and refractory nausea and vomiting describe the symptoms of uncontrolled emesis. Evidence suggests that good control of nausea and vomiting during the acute period correlates with the control of delayed emesis. Conversely, protection failure during the first 24 hours has a high predictive value for delayed emesis in the same cycle.The 5-HT 3 -receptor antagonists, regarded as the 'gold standard' in antiemetic therapy, are the first-line treatment for moderately and highly emetogenic chemotherapy and radiotherapy regimens in adults and children. Evidence suggests that the 5-HT 3 -receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.Antiemetic therapeutic guidelines stress that the goal of therapy is to prevent cytostatic-induced nausea and vomiting. Therefore, the prophylactic use of the most effective antiemetic regimen-taking into consideration the emetogenicity of the chemotherapy and individual patient characteristics-must be adhered to in order to prevent acute, delayed, and anticipatory nausea and vomiting.

show abstract

“…Moreover, studies comparing granisetron, 40 and 160 mg kg 71 , show a trend towards increased efficacy at the higher dose Soukop, 1994); 24 h after administration of chemotherapeutic agents, 81% of granisetron, 160 mcg kg 71 , were emesis-free compared with 75% receiving granisetron 40 mg kg 71 . In addition, patients refractory to other 5-HT 3 receptor antagonists have been shown to respond well to granisetron, at doses that are higher than generally used, in subsequent chemotherapy cycles (Carmichael et al, 1998).…”

Section: Sirmentioning

confidence: 99%

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

Blower

Aapro

2002

Br J Cancer

View full text Add to dashboard Cite

show abstract

Use of granisetron in patients refractory to previous treatment with antiemetics

Cited by 90 publications

References 0 publications

A Comparative Study of Ondansetron and Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day-Care Surgery

A Comparative Study of Ondansetron and Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day-Care Surgery

Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

Contact Info

Product

Resources

About